HLA-A and non-small cell lung carcinoma: Furthermore, it is estimated that approximately 15% of Asian NSCLC patients with EGFR mutations exhibit both the HLA-A*11:01 and p.L858R mutations, pointing to a significant subset of patients who could benefit from tailored therapeutic strategies [157,158].